Clinical trial information: NCT04440735 .doi:10.1200/jco.2023.41.16_suppl.2632A. SaeedB. BashirJ. LukeReuven ChantreS. AmsiliR. TabakmanYaffa ShwartzA. Foley-ComerA. JimenoAmerican Society of Clinical OncologyJournal of Clinical Oncology
Clinical trial information: NCT04440735.doi:10.1200/JCO.2022.40.16_suppl.2647Jason J. LukeAnwaar SaeedBabar BashirYaffa ShwartzRinat TabakmanAdam Foley-ComerAntonio JimenoAmerican Society of Clinical OncologyJournal of Clinical Oncology
However, treatment with a CD47 monoclonal antibody in combination with rituximab yielded high objective response rates in patients with relapsed/refractory DLBCL in a phase I trial. Here, we report on a new bispecific and fully human fusion protein comprising the extracellular domains of SIRP伪 and...